Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.

Carles Moliner-AbósMercedes Rivas-LasarteJulia Pamies BesoraPaula Fluvià-BruguesEduard Solé-GonzálezSonia MirabetLaura López LópezVicens BrossaMaria José PirlaNuria MesadoJesus Alvarez-GarciaEulàlia Roig

Published in: Cardiovascular drugs and therapy (2020)

Sacubitril/valsartan in real-life is prescribed to a more advanced HF population, which could be responsible for the difficulties in reaching high doses of the drug. However, after a 6-month follow-up, sacubitril/valsartan significantly reduces HF hospitalization and induces cardiac reverse remodeling, without remarkable adverse events.

Keyphrases

systematic review
ejection fraction
heart failure
acute heart failure
left ventricular
meta analyses
primary care
healthcare
quality improvement
cardiac resynchronization therapy
drug induced
adverse drug